MIN JINHAMIN JIN HA11877HA, MIN JINAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBiostatisticsExperimental Radiation OncologyInvestigational Cancer TherapeuticsLeukemiaSystems BiologyThoracic & Cardiovascular SurgeryThoracic Head & Neck Medical OncologyTranslational Molecular PathologyMD AndersonKIM-ANHDOKIM-ANH DO8794DO, KIM-ANHProfessorJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorVEERABHADRANBALADANDAYUTHAPANIVEERABHADRAN BALADANDAYUTHAPANI9283BALADANDAYUTHAPANI, VEERABHADRANAssociate ProfessorJACK AROTHJACK A ROTH8498ROTH, JACK AProfessorKHANDANKEYOMARSIKHANDAN KEYOMARSI8908KEYOMARSI, KHANDANProfessorIGNACIO IVANWISTUBAIGNACIO IVAN WISTUBA9098WISTUBA, IGNACIO IVANProfessor25861215Ha MJ, Baladandayuthapani V, Do KACancer informaticsPrognostic gene signature identification using causal structure learning: applications in kidney cancer. Cancer Inform. 2015; 14(Suppl 1):23-35.Cancer Inform2015-01-27T00:00:002015Prognostic gene signature identification using causal structure learning: applications in kidney cancer.26148744Ha MJ, Baladandayuthapani V, Do KABioinformatics (Oxford, England)DINGO: differential network analysis in genomics. Bioinformatics. 2015 Nov 01; 31(21):3413-20.Bioinformatics2015-07-06T00:00:002015DINGO: differential network analysis in genomics.74Professor10Assistant Professor14Associate Professor1400 Pressler StHouston77030-4008TX0.842980.00968192173research areas2.316960.036515257coauthor of27.93947.6157860similar to1140selected publications27881578Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi KClinical cancer research : an official journal of the American Association for Cancer ResearchCytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002.Clin Cancer Res2016-11-23T00:00:002016Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.Authorship 847788Authorship 851801Authorship 867685Authorship 868143BioinformaticsDINGO. Bioinformatics. 31:3413-3420.DINGOBiometricsPenPC. Biometrics. PenPCCancer InformaticsPrognostic gene signature identification using causal structure learning. Cancer Informatics. 14:23-35.Prognostic gene signature identification using causal structure learningBiometricsPartial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation. Biometrics. 70:765-773.Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimationAuthorship 8870311Authorship 8873501Authorship 8877513D020869Procedures125051650.411295Gene Expression ProfilingD003627Concepts & Ideas2994800.813871Data Interpretation, StatisticalAuthorship 9041251Authorship 9075813Authorship 9272072Authorship 9326733Authorship 9330061Authorship 935878126406114Ha MJ, Sun W, Xie JBiometricsPenPC: A two-step approach to estimate the skeletons of high-dimensional directed acyclic graphs. Biometrics. 2016 Mar; 72(1):146-55.Biometrics2015-09-25T00:00:002015PenPC: A two-step approach to estimate the skeletons of high-dimensional directed acyclic graphs.27342398Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi VClinical cancer research : an official journal of the American Association for Cancer ResearchIdelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res. 2017 Jan 01; 23(1):181-192.Clin Cancer Res2016-06-24T00:00:002016Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.29194470Class CA, Ha MJ, Baladandayuthapani V, Do KABioinformatics (Oxford, England)iDINGO-integrative differential network analysis in genomics with Shiny application. Bioinformatics. 2018 04 01; 34(7):1243-1245.Bioinformatics2018-04-01T00:00:002018iDINGO-integrative differential network analysis in genomics with Shiny application.30051914Kim J, Do KA, Ha MJ, Peterson CBBiometricsBayesian inference of hub nodes across multiple networks. Biometrics. 2019 03; 75(1):172-182.Biometrics2018-08-23T00:00:002018Bayesian inference of hub nodes across multiple networks.30596892Ha MJ, Sun WBiostatistics (Oxford, England)Estimation of high-dimensional directed acyclic graphs with surrogate intervention. Biostatistics. 2020 10 01; 21(4):659-675.Biostatistics2020-10-01T00:00:002020Estimation of high-dimensional directed acyclic graphs with surrogate intervention.30297783Ha MJ, Banerjee S, Akbani R, Liang H, Mills GB, Do KA, Baladandayuthapani VScientific reportsPersonalized Integrated Network Modeling of the Cancer Proteome Atlas. Sci Rep. 2018 10 08; 8(1):14924.Sci Rep2018-10-08T00:00:002018Personalized Integrated Network Modeling of the Cancer Proteome Atlas.D019295Occupations50912690.610709Computational BiologyAuthorship 941343630867218Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi KClinical cancer research : an official journal of the American Association for Cancer ResearchCombined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019 07 01; 25(13):3996-4013.Clin Cancer Res2019-03-13T00:00:002019Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.D00007169653870.918132ProteogenomicsD060066Concepts & Ideas1131490.904294Protein Interaction MapsAuthorship 948972531178611Ni Y, Stingo FC, Ha MJ, Akbani R, Baladandayuthapani VJournal of the American Statistical AssociationBayesian Hierarchical Varying-sparsity Regression Models with Application to Cancer Proteogenomics. J Am Stat Assoc. 2019; 114(525):48-60.J Am Stat Assoc2018-08-15T00:00:002018Bayesian Hierarchical Varying-sparsity Regression Models with Application to Cancer Proteogenomics.31186248Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JACancer immunology researchAn Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res. 2019 08; 7(8):1267-1279.Cancer Immunol Res2019-06-11T00:00:002019An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses.Authorship 954243331436549Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KKAnnals of surgeryCytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159.Ann Surg2021-08-01T00:00:002021Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.31797633Liu Q, Ha MJ, Bhattacharyya R, Garmire L, Baladandayuthapani VPacific Symposium on Biocomputing. Pacific Symposium on BiocomputingNetwork-Based Matching of Patients and Targeted Therapies for Precision Oncology. Pac Symp Biocomput. 2020; 25:623-634.Pac Symp Biocomput2020-01-01T00:00:002020Network-Based Matching of Patients and Targeted Therapies for Precision Oncology.Authorship 986594432253074Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng CD, Aloia TA, Ueno NT, Kuerer HM, Barcenas CH, Vauthey JNEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyHepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol. 2020 09; 46(9):1588-1595.Eur J Surg Oncol2020-03-28T00:00:002020Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.32374631Bhattacharyya R, Ha MJ, Liu Q, Akbani R, Liang H, Baladandayuthapani VJCO clinical cancer informaticsPersonalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome. JCO Clin Cancer Inform. 2020 05; 4:399-411.JCO Clin Cancer Inform2020-05-01T00:00:002020Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome.Authorship 9900792Authorship 9900852Authorship 9900983Authorship 990111124845967Ha MJ, Sun WBiometricsPartial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation. Biometrics. 2014 Sep; 70(3):765-73.Biometrics2014-05-20T00:00:002014Partial correlation matrix estimation using ridge penalty followed by thresholding and re-estimation.Authorship 999217732903557Jones RJ, Singh RK, Shirazi F, Wan J, Wang H, Wang X, Ha MJ, Baljevic M, Kuiatse I, Davis RE, Orlowski RZFrontiers in immunologyIntravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors. Front Immunol. 2020; 11:1816.Front Immunol2020-08-13T00:00:002020Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.Authorship 1007892133371887Ha MJ, Kim J, Galloway-Pe?a J, Do KA, Peterson CBBMC bioinformaticsCompositional zero-inflated network estimation for microbiome data. BMC Bioinformatics. 2020 Dec 28; 21(Suppl 21):581.BMC Bioinformatics2020-12-28T00:00:002020Compositional zero-inflated network estimation for microbiome data.Authorship 1008443933415011Zhang X, Zhang R, Chen H, Wang L, Ren C, Pataer A, Wu S, Meng QH, Ha MJ, Morris J, Xi Y, Wang J, Zhang J, Gibbons DL, Heymach JV, Meric-Bernstam F, Minna J, Swisher SG, Roth JA, Fang BAmerican journal of cancer researchKRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.Am J Cancer Res2020-12-01T00:00:002020KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.Authorship 10172891233916118Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi KCancersTargeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel). 2021 Apr 01; 13(7).Cancers (Basel)2021-04-01T00:00:002021Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.33990543Lulla AR, Akli S, Karakas C, Ha MJ, Fowlkes NW, Mitani Y, Bui T, Wang J, Rao X, Hunt KK, Meijer L, El-Naggar AK, Keyomarsi KOncogenesisLMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 2021 May 14; 10(5):40.Oncogenesis2021-05-14T00:00:002021LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers.Authorship 10185104Authorship 1023540134239216Ha MJ, Stingo FC, Baladandayuthapani VJournal of the American Statistical AssociationBayesian Structure Learning in Multi-layered Genomic Networks. J Am Stat Assoc. 2021; 116(534):605-618.J Am Stat Assoc2020-07-24T00:00:002020Bayesian Structure Learning in Multi-layered Genomic Networks.Authorship 10298423034526717Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JVNatureStructure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.Nature2021-09-15T00:00:002021Structure-based classification predicts drug response in EGFR-mutant NSCLC.Authorship 10395681Authorship 10404887Authorship 10410705Authorship 10416662235133007Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi KInternational journal of cancerPalbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer. 2022 06 15; 150(12):2025-2037.Int J Cancer2022-03-03T00:00:002022Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.35210547Meraz IM, Majidi M, Shao R, Meng F, Ha MJ, Shpall E, Roth JACommunications biologyTUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Commun Biol. 2022 02 24; 5(1):167.Commun Biol2022-02-24T00:00:002022TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model.35349735Lee SH, Yim SY, Jeong YS, Li QX, Kang SH, Sohn BH, Kumar SV, Shin JH, Choi YR, Shim JJ, Kim H, Kim JH, Kim S, Guo S, Johnson RL, Kaseb A, Kang KJ, Chun YS, Jang HJ, Lee BG, Woo HG, Ha MJ, Akbani R, Roberts LR, Wheeler DA, Lee JSHepatology (Baltimore, Md.)Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology. 2022 12; 76(6):1634-1648.Hepatology2022-06-29T00:00:002022Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes.35075200Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam FScientific reportsCombined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.Sci Rep2022-01-24T00:00:002022Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.Authorship 1044921235498876Long JP, Ha MJStatistical analysis and data miningSample Selection Bias in Evaluation of Prediction Performance of Causal Models. Stat Anal Data Min. 2022 Feb; 15(1):5-14.Stat Anal Data Min2021-10-20T00:00:002021Sample Selection Bias in Evaluation of Prediction Performance of Causal Models.Authorship 1051397635906256Huang L, Wang J, Fang B, Meric-Bernstam F, Roth JA, Ha MJScientific reportsCombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.Sci Rep2022-07-29T00:00:002022CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.Authorship 1054531636648331Huang L, Long JP, Irajizad E, Doecke JD, Do KA, Ha MJBioinformatics (Oxford, England)A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes. Bioinformatics. 2023 01 01; 39(1).Bioinformatics2023-01-01T00:00:002023A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes.Authorship 10706631137169941Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JACommunications biology3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 05 11; 6(1):509.Commun Biol2023-05-11T00:00:0020233-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.Authorship 10741321137280434Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JACommunications biologyAuthor Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 Jun 06; 6(1):608.Commun Biol2023-06-06T00:00:002023Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.Authorship 1083678937980453Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Ha MJ, Chen H, Ng PKS, DiPeri TP, Mills GB, Rodon Ahnert J, Damodaran S, Meric-Bernstam FScientific reportsEfficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep. 2023 11 18; 13(1):20223.Sci Rep2023-11-18T00:00:002023Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.Authorship 1086155538172226Kim J, Hurh K, Kim H, Park EC, Ha MJScientific reportsEffect of the peripartum depressive symptoms on the Internet use disorder of their offspring in late childhood: retrospective longitudinal study. Sci Rep. 2024 01 03; 14(1):417.Sci Rep2024-01-03T00:00:002024Effect of the peripartum depressive symptoms on the Internet use disorder of their offspring in late childhood: retrospective longitudinal study.Authorship 10886541838331987Thongon N, Ma F, Baran N, Lockyer P, Liu J, Jackson C, Rose A, Furudate K, Wildeman B, Marchesini M, Marchica V, Storti P, Todaro G, Ganan-Gomez I, Adema V, Rodriguez-Sevilla JJ, Qing Y, Ha MJ, Fonseca R, Stein C, Class C, Tan L, Attanasio S, Garcia-Manero G, Giuliani N, Berrios Nolasco D, Santoni A, Cerchione C, Bueso-Ramos C, Konopleva M, Lorenzi P, Takahashi K, Manasanch E, Sammarelli G, Kanagal-Shamanna R, Viale A, Chesi M, Colla SNature communicationsTargeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nat Commun. 2024 Feb 08; 15(1):1203.Nat Commun2024-02-08T00:00:002024Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor